SIRPA and cancer: Despite the successful application of anti-CD47 and anti-SIRPα blocking antibodies in immunotherapy against cancer cells, the potential of engaging SIRPα to restrain excessive immune activation in the context of ILC2s and allergic lung inflammation remains unexplored.